BVS
Bioventus Inc.
NASDAQ · Healthcare · Medical - Devices · US
$10.95
−16.77%Year over year
Reported trailing growth
- Revenue
- +3.9%
- EBITDA
- +2.1%
- EBIT
- +36.0%
- EPS
- +635.3%
- Free cash flow
- +58.9%
- Operating cash flow
- +56.1%
Forward estimates
Based on analyst estimates
- Revenue
- +7.9%
- EBITDA
- +35.7%
- EPS
- -0.1%
Three-year CAGR
- Revenue
- +3.5%
- EBITDA
- +152.9%
- EBIT
- +588.7%
- Net income
- +167.8%
- EPS
- +165.4%
- Free cash flow
- +199.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026